Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.50
Bid: 32.00
Ask: 33.00
Change: -3.00 (-8.45%)
Spread: 1.00 (3.125%)
Open: 35.50
High: 35.50
Low: 32.50
Prev. Close: 35.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: YouGov, Sareum and InterQuest...

Tue, 07th Aug 2012 11:25

Environmental Recycling Technologies, which owns the rights to the Powder Impression Moulding (PIM) process which is capable of converting mixed waste plastics into commercially viable products, has confirmed that its US parent application, entitled 'Process for Forming Plastic, Apparatuses for Forming Plastic and Articles Made Therefrom', has been granted by the US Patent Office. This is ERT's core patent in the US for the PIM process. Sareum, a specialist cancer drug discovery business, has said it notes the recent significant rise in its share price and has confirmed that "advanced stages of negotiations are taking place with a potential licencing partner". It added these "may or may not lead to a licencing agreement regarding one of the company's research programmes". Shares were up 184% on Tuesday, equal to 1.15p. The stock has gained 42% over the past year, and 163% in the past month. YouGov, the online market research firm, is anticipating that its operating profit will be in line with expectations with second half revenue similar to that achieved in the first half, reflecting the firm's focus on profitability in the German business and the expected end to a long-term contract in Iraq. The firm said its balance sheet remains strong with cash at July 31st of around £7.0m. TClarke, a building services company, reported a decline in pre-tax profit for the half year at £0.5m (2011: £1.4m) on revenues of £90.7m (2011: £92.6m), with the profit margin also lower at 0.5% compared to 1.5% the previous year. Basic earnings per share dropped from 2.38p to 0.79p, while net cash climbed £0.1m to £0.7m. The interim dividend was maintained at 1p per share. The firm blamed a lack of confidence across the sector for the declines and said that with a number of projects due to begin shortly it is confident of significant revenue progress in the second half. Shares in InterQuest Group, a specialist information technology recruitment group, took a hit after it admitted earnings before interest, tax, depreciation and amortisation are expected to be down year-on-year, in the region of £1.15m (2011: £1.86m), and warned the impact of investments and restructuring on profitability for 2012 will be around £1.6m. Trading conditions were poor in both the UK and Far East, particularly in the second quarter and particularly in the banking and finance sectors from which it derives 27% of its net fee income. This has meant profitability from investments has taken longer than anticipated. NR
More News
13 Jun 2019 15:49

Sareum Plans To Start Human Trials Of Two Drug Candidates In 2020

(Alliance News) - Sareum Holdings PLC on Thursday said it has been focusing on toxicology studies in its development of drug candidates SDC-1801 and SDC-1802 with a view to CONDUCT human trials in

Read more
3 Jun 2019 17:38

Sareum Notes Sierra Oncology's Positive Preliminary Results Of SRA737

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it noted its licensee Sierra Oncology's webcast discussing clinical findings and possible next steps for SRA737, its oral checkpoint

Read more
3 Jun 2019 10:02

Sareum Reports Positive Data From Trials Of SRA737 In Advanced Cancer

LONDON (Alliance News) - Sareum Holdings PLC on Monday said that Sierra Oncology reported positive preliminary clinical data from two in-human studies of SRA737.Shares in the drug company a

Read more
4 Mar 2019 10:58

Sareum Interim Loss Deepens On Costs As Pipeline Continues Progress

LONDON (Alliance News) - Cancer drug discovery firm Sareum Holdings PLC said Monday its interim loss widened as costs rose, but it made progress with its key developmental programmes.For to

Read more
4 Mar 2019 08:26

Sareum's loss widens as development costs expand

(Sharecast News) - Sareum Holdings' shares dropped on Monday after the company reported a widened interim loss due to rising costs, though it stated progress had been made with key development programmes.

Read more
28 Feb 2019 14:33

Sareum flags potentially significant findings for SRA737

(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Thursday that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, had reported that an abstract reporting preclinical data for SRA737 - its Chk1 inhibitor - plus low dose gemcitabine (LDG), in combination with immunotherapy, had been selected for a late-breaking oral presentation at the American Association of Cancer Research annual meeting.

Read more
11 Dec 2018 15:55

UK Shareholder Meetings Calendar - Next 7 Days

Wednesday 12 DecemberBlancco Technology GroupBellwayVolution Shopping REIT (re voluntary 13 Asian 14 to

Read more
30 Nov 2018 11:48

Sareum Reports Efficacy Data For Immunotherapy Combination With SRA737

LONDON (Alliance News) - Sareum Holdings PLC said Friday that Sierra Oncology Inc reported preclinical efficacy data for an immunotherapy combination with its SRA737 inhibitor in lung licences the

Read more
26 Oct 2018 09:20

Sareum Holdings Raises GBP850,000 Via Share Placing (ALLISS)

LONDON (Alliance News) - Sareum Holdings PLC said Friday it raised GBP850,000 via the issue of 130.8 million shares to fund the development of its lead cancer and autoimmune drugs.The drug

Read more
26 Oct 2018 08:38

Sareum raises £850,000 to fund cancer inhibitor

(Sharecast News) - Drug maker Sareum has raised £850,000 to progress the development programme of its cancer inhibitor TYK2/JAK1.

Read more
1 Oct 2018 11:30

Sareum Swings To Annual Loss After Prior Year Profit From Associates

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it swung to an annual loss after reporting a substantial share of profit from associates the year before.Shares in Sareum were at

Read more
26 Sep 2018 15:20

Sareum Holdings selects cancer therapy development candidate

(Sharecast News) - Drug discovery and development company Sareum Holdings has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new targeted therapy for certain cancers, it announced on Wednesday.

Read more
26 Sep 2018 14:05

Sareum Selects Candidate To Develop Cancer Treatment

LONDON (Alliance News) - Sareum Holdings PLC said Wednesday that it has selected the SDC-1802 molecule from the TYK2 inhibitor programme for further development as potential treatment for certain

Read more
11 Sep 2018 13:28

Sareum Holdings Expects To Swing To GBP1.5 Million Annual Loss

LONDON (Alliance News) - Sareum Holdings PLC said Tuesday it expects to report a loss in its annual results as it progresses on its programmes in autoimmune diseases and cancer.The drug it

Read more
10 Sep 2018 11:52

Sareum Picks SDC-1801 For Development As Autoimmune Disease Treatment

LONDON (Alliance News) - Sareum Holdings PLC said Monday it will develop SDC-1801 as a possible treatment for autoimmune diseases.The molecule, SDC-1801, has been formally selected for is a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.